» Articles » PMID: 34889363

What else Do I Need to Worry About when Treating Graft-versus-host Disease?

Overview
Specialty Hematology
Date 2021 Dec 10
PMID 34889363
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Graft-versus-host disease (GVHD) is the main cause of morbidity and mortality in allogeneic hematopoietic stem cell transplant survivors. Patients with acute and chronic GVHD often endure substantial symptom burden and quality of life (QOL) and functional impairments. Living with GVHD affects multiple domains of patient-reported QOL, physical functioning, and psychological well-being. Patients describe living with GVHD as a life-altering "full-time job" requiring unique knowledge, personal growth, and resilient coping strategies. Managing the supportive care needs of patients living with GVHD must include (1) monitoring of patient-reported QOL and symptom burden; (2) routine screening for psychological distress and implementing therapeutic strategies to treat depression, anxiety, and posttraumatic stress symptoms; (3) a systematic review of care needs by a multidisciplinary team experienced in managing transplant-related complications and organ-specific GVHD symptoms; and (4) ensuring optimal prevention and management of infection complications in this highly immunocompromised population. Improving the QOL in patients with GVHD requires a multidisciplinary approach with emphasis on aggressive symptom management, psychological coping, and promoting physical activity and rehabilitation in this population living with immense prognostic uncertainty and struggling to adapt to this difficult and unpredictable illness.

Citing Articles

"They knew the same struggles": perceptions of a group coping skills intervention in patients with chronic graft-versus-host disease.

Centracchio J, Yang D, Jagielo A, Greer J, El-Jawahri A, Traeger L Support Care Cancer. 2025; 33(2):102.

PMID: 39814942 PMC: 11735584. DOI: 10.1007/s00520-025-09153-x.


Allogeneic Stem Cell Transplant in Hematological Disorders: A Decade of Experience.

Arif S, Ali N, Shaikh U, Adil S, Jehanzeb H Int J Hematol Oncol Stem Cell Res. 2024; 18(4):344-357.

PMID: 39703474 PMC: 11652702. DOI: 10.18502/ijhoscr.v18i4.16759.


Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease.

Shah R, Murphy D, Logue M, Jerkins J, Jallouk A, Adetola K Clin Hematol Int. 2024; 6(4):74-88.

PMID: 39469117 PMC: 11514143. DOI: 10.46989/001c.124926.


Group Coping Intervention in Patients With Chronic Graft-Versus-Host Disease: A Pilot Randomized Clinical Trial.

Nelson A, Yang D, Jagielo A, DAlotto J, Poliquin C, Rabideau D J Natl Compr Canc Netw. 2024; 22(1):34-42.

PMID: 38394783 PMC: 11112519. DOI: 10.6004/jnccn.2023.7080.


Understanding the Needs and Lived Experiences of Patients With Graft-Versus-Host Disease: Real-World European Public Social Media Listening Study.

Peric Z, Basak G, Koenecke C, Moiseev I, Chauhan J, Asaithambi S JMIR Cancer. 2023; 9:e42905.

PMID: 37948101 PMC: 10674148. DOI: 10.2196/42905.


References
1.
Sullivan K, Witherspoon R, Storb R, Weiden P, Flournoy N, Dahlberg S . Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988; 72(2):546-54. View

2.
. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep. 2001; 49(RR-10):1-125, CE1-7. View

3.
Hamada R, Kondo T, Murao M, Miyasaka J, Yoshida M, Nankaku M . Effect of the severity of acute graft-versus-host disease on physical function after allogeneic hematopoietic stem cell transplantation. Support Care Cancer. 2019; 28(7):3189-3196. DOI: 10.1007/s00520-019-05124-1. View

4.
Lee S, Flowers M . Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2008; :134-41. DOI: 10.1182/asheducation-2008.1.134. View

5.
Chiodi S, Spinelli S, Ravera G, Petti A, Van Lint M, Lamparelli T . Quality of life in 244 recipients of allogeneic bone marrow transplantation. Br J Haematol. 2000; 110(3):614-9. DOI: 10.1046/j.1365-2141.2000.02053.x. View